Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR112 in relapsed advanced lymphoma
NCT06755450Phase 1Recruiting
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AUR-112 in lymphoma, chronic lymphocytic leukemia (CLL) and Hodgkin lymphoma (HL), sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 28 days and 9 more. Started Jan 2025; status: recruiting.
02
Drugs
AUR-112
03
Conditions
lymphomachronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT06755450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06755450.